The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Medvedev S.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Khmelevsky E.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Kaprin A.D.

National Medical Research Radiology Centre;
People’s Friendship University of Russia

Troshenkov E.A.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Russia

Abusheva E.R.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Vlasova M.Yu.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Russia

Maslov E.D.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Markov S.E.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Gashimova P.N.

Peoples’ Friendship University of Russia named after Patrice Lumumba

Guseva S.D.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Andreanova E.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Hypofractionate radiotherapy for a rare malignant neoplasm of epidermal origin — keratoacanthoma of the skin

Authors:

Medvedev S.V., Khmelevsky E.V., Kaprin A.D., Troshenkov E.A., Abusheva E.R., Vlasova M.Yu., Maslov E.D., Markov S.E., Gashimova P.N., Guseva S.D., Andreanova E.V.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2024;13(4): 48‑53

Read: 1239 times


To cite this article:

Medvedev SV, Khmelevsky EV, Kaprin AD, et al. Hypofractionate radiotherapy for a rare malignant neoplasm of epidermal origin — keratoacanthoma of the skin. P.A. Herzen Journal of Oncology. 2024;13(4):48‑53. (In Russ.)
https://doi.org/10.17116/onkolog20241304148

Recommended articles:
Proton therapy of skull base chordoma. P.A. Herzen Journal of Onco­logy. 2025;(5):64-67
Lean mana­gement example at the radiotherapy depa­rtment. Medi­cal Technologies. Asse­ssment and Choice. 2025;(2):67-73
Prevention and treatment of dermal toxi­city in children receiving anti-tumor radiation. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):470-480
Non-melanoma skin cancer: part 1, lite­rature review. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(5):558-564
Tongue reco­nstruction using radial forearm flap. Plastic Surgery and Aesthetic Medi­cine. 2025;(4):74-78
Non-melanoma skin cancer (part 2). Russian Journal of Clinical Dermatology and Vene­reology. 2025;(6):808-813
Hypo­fractionated irra­diation for intracranial meni­ngiomas. Burdenko's Journal of Neurosurgery. 2025;(6-2):21-28
Overall survival prediction scale for patients with grade 4 brain astrocytoma. Burdenko's Journal of Neurosurgery. 2026;(1):65-72

References:

  1. Hodak E, Jones RE, Ackerman AB. Solitary keratoacanthoma is a squamous-cell carcinoma: three examples with metastases. Am J Dermatopathol. 1993;15(4):332-342; discussion 343-352.  https://doi.org/10.1097/00000372-199308000-00007
  2. Karaa A, Khachemoune A. Keratoacanthoma: a tumor in search of a classification. Int J Dermatol. 2007;46(7):671-678.  https://doi.org/10.1111/j.1365-4632.2007.03260.x
  3. Ra SH, Su A, Li X, Zhou J, Cochran AJ, Kulkarni RP, Binder SW. Keratoacanthoma and squamous cell carcinoma are distinct from a molecular perspective. Mod Pathol. 2015;28(6):799-806.  https://doi.org/10.1038/modpathol.2015.5
  4. Elder DE, Massi D, Scolyer RA, Willemze R, eds. WHO classification of skin tumours. 4th ed. Vol. 11. IARC Publications; 2018.
  5. Yunusova EI, Yusupova LA, Garaeva ZSh, Mavlyutova GI. Keratoacanthoma: clinic, diagnosis, therapy. Far Eastern Medical Journal. 2021;(2):78-81. (In Russ.). https://doi.org/10.35177/1994-5191-2021-2-78-81
  6. Kwittken J. A histologic chronology of the clinical course of the keratocarcinoma (so-called keratoacanthoma). Mt Sinai J Med. 1975;42(2):127-135. 
  7. Goldschmidt H, Sherwin WK. Radiation therapy of giant aggressive keratoacanthomas. Arch Dermatol. 1993;129(9):1162-1165.
  8. Craddock KJ, Rao J, Lauzon GJ, Tron VA. Multiple keratoacanthomas arising post-UVB therapy. J Cutan Med Surg. 2004;8(4):239-243.  https://doi.org/10.1007/s10227-004-0122-8
  9. Magee KL, Rapini RP, Duvic M, Adler-Storthz K. Human papillomavirus associated with keratoacanthoma. Arch Dermatol. 1989;125(11):1587-1589.
  10. Goldberg LH, Silapunt S, Beyrau KK, Peterson SR, Friedman PM, Alam M. Keratoacanthoma as a postoperative complication of skin cancer excision. J Am Acad Dermatol. 2004;50(5):753-758.  https://doi.org/10.1016/j.jaad.2003.11.065
  11. Schwartz RA. Keratoacanthoma. J Am Acad Dermatol. 1994;30(1):1-19; quiz 20-22.  https://doi.org/10.1016/s0190-9622(94)70001-x
  12. Melendez ND, Smoller BR, Morgan M. VCAM (CD-106) and ICAM (CD-54) adhesion molecules distinguish keratoacanthomas from cutaneous squamous cell carcinomas. Mod Pathol. 2003;16(1):8-13.  https://doi.org/10.1097/01.MP.0000043520.74056.CD
  13. Gray RJ, Meland NB. Topical 5-fluorouracil as primary therapy for keratoacanthoma. Ann Plast Surg. 2000;44(1):82-85.  https://doi.org/10.1097/00000637-200044010-00015
  14. Thiele JJ, Ziemer M, Fuchs S, Elsner P. Combined 5-fluorouracil and Er:YAG laser treatment in a case of recurrent giant keratoacanthoma of the lower leg. Dermatol Surg. 2004;30(12 Pt. 2):1556-1560. https://doi.org/10.1111/j.1524-4725.2004.30559.x
  15. Radakovic-Fijan S, Hönigsmann H, Tanew A. Efficacy of topical photodynamic therapy of a giant keratoacanthoma demonstrated by partial irradiation. Br J Dermatol. 1999;141(5):936-938.  https://doi.org/10.1046/j.1365-2133.1999.03180.x
  16. Jia X, Ge Y, Wang H, Ma Y. Radiotherapy for keratoacanthoma of facial skin: a case report and review of literature. Front Oncol. 2023;12:1032090. https://doi.org/10.3389/fonc.2022.1032090
  17. Grevelhörster T, Micke O, Hampel G, Schönekaes K, Willich N. Hochdosierte multimodale Radiotherapie konfluierend-destruierend wachsender, aggregierter Keratoakanthome, Zwei Falldarstellungen [High-dose multimodal radiotherapy of confluent destructively growing aggregated keratoacanthoma. 2 case reports]. Strahlenther Onkol. 1996;172(7):395-400. (In German).
  18. Donahue B, Cooper JS, Rush S. Treatment of aggressive keratoacanthomas by radiotherapy. J Am Acad Dermatol. 1990;23(3 Pt. 1):489-493.  https://doi.org/10.1016/0190-9622(90)70247-f
  19. Gunaratne DA, Veness MJ. Efficacy of hypofractionated radiotherapy in patients with non-melanoma skin cancer: results of a systematic review. J Med Imaging Radiat Oncol. 2018;62(3):401-411.  https://doi.org/10.1111/1754-9485.12718
  20. Paravati AJ, Hawkins PG, Martin AN, et al. Clinical and cosmetic outcomes in patients treated with high-dose-rate electronic brachytherapy for nonmelanoma skin cancer. Pract Radiat Oncol. 2015;5(6):e659-e664. https://doi.org/10.1016/j.prro.2015.07.002

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.